GlaxoSmithKline’s experience of incurred sample reanalysis for dried blood spot samples-Reference-Cited by-同舟云学术

GlaxoSmithKline’s experience of incurred sample reanalysis for dried blood spot samples

Published:2011-05 Issue:9 Volume:3 Page:1025-1030
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Barfield Matthew,Ahmad Sheelan¹,Busz Maria²

Affiliation:

1. Platform Technology & Science, Drug Metabolism & Pharmacokinetics, Worldwide Bioanalysis & Systems Management, GlaxoSmithKline Pharmaceuticals, Park Road, Ware, Hertfordshire, SG12 0DP, UK

2. Platform Technology & Science, Drug Metabolism & Pharmacokinetics, Worldwide Bioanalysis & Systems Management, GlaxoSmithKline Pharmaceuticals, PA, USA

Abstract

Dried blood spots are becoming a popular alternative to plasma for many different applications. This has been driven by animal ethics but also by ease of use and cost savings. Recent regulatory guidance now has a requirement for incurred sample reanalysis. This article details three examples of incurred sample reanalysis using dried blood spot samples.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio.11.56

Reference16 articles.

1. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules

2. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice

3. Facilitating pharmacokinetic studies in children: a new use of dried blood spots

4. Use of Dried Blood Spots in Drug Development: Pharmacokinetic Considerations

5. Pharmacokinetic considerations as to when to use dried blood spot sampling

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular dynamics simulations to explore the binding mode between the amyloid-β protein precursor (APP) and adaptor protein Mint2;Scientific Reports;2024-04-04

2. Incurred sample reanalysis (ISR) in clinical bioanalysis—Is it really a one‐size‐fits‐all solution?;Biomedical Chromatography;2024-02-05

3. Opportunities and obstacles for microsampling techniques in bioanalysis: Special focus on DBS and VAMS;Journal of Pharmaceutical and Biomedical Analysis;2020-04

4. Microsampling: considerations for its use in pharmaceutical drug discovery and development;Bioanalysis;2019-05

5. A decade of incurred sample reanalysis: failures, investigations and impact;Bioanalysis;2018-11-01